Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
FDA provides favorable input on studies to support ANEB-001 approval Part C Extension of Phase 2 trial completed exploring THC challenge dose of up to 60 mg AUSTIN, Texas–(BUSINESS WIRE)–Anebulo…
Details